CAM Group Holding A S maintained its position in Aerie Pharmaceuticals Inc. (NASDAQ:AERI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 192,006 shares of the company’s stock at the end of the second quarter. CAM Group Holding A S’s holdings in Aerie Pharmaceuticals were worth $3,379,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of the company. Spark Investment Management LLC acquired a new position in Aerie Pharmaceuticals during the first quarter worth approximately $1,968,000. Kennedy Capital Management Inc. increased its stake in Aerie Pharmaceuticals by 14.3% in the first quarter. Kennedy Capital Management Inc. now owns 54,296 shares of the company’s stock worth $660,000 after buying an additional 6,787 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Aerie Pharmaceuticals by 24.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,025,000 shares of the company’s stock worth $24,624,000 after buying an additional 400,000 shares during the last quarter. A.R.T. Advisors LLC increased its stake in Aerie Pharmaceuticals by 126.7% in the first quarter. A.R.T. Advisors LLC now owns 172,032 shares of the company’s stock worth $2,091,000 after buying an additional 96,145 shares during the last quarter. Finally, Deerfield Management Co. increased its stake in Aerie Pharmaceuticals by 225.9% in the first quarter. Deerfield Management Co. now owns 2,632,482 shares of the company’s stock worth $32,011,000 after buying an additional 1,824,607 shares during the last quarter. 95.28% of the stock is currently owned by institutional investors.
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) traded down 2.79% on Wednesday, reaching $35.52. The company’s stock had a trading volume of 645,455 shares. Aerie Pharmaceuticals Inc. has a 52-week low of $10.82 and a 52-week high of $41.72. The stock’s market cap is $990.72 million. The firm’s 50-day moving average price is $32.43 and its 200-day moving average price is $20.86.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.02. On average, equities analysts expect that Aerie Pharmaceuticals Inc. will post ($2.81) earnings per share for the current year.
A number of research firms have recently weighed in on AERI. Cantor Fitzgerald restated a “buy” rating and set a $50.00 target price on shares of Aerie Pharmaceuticals in a research report on Saturday, October 8th. Stifel Nicolaus boosted their target price on Aerie Pharmaceuticals from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, October 6th. Brean Capital restated a “buy” rating and set a $63.00 target price (up previously from $48.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, October 6th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 4th. Finally, HC Wainwright began coverage on Aerie Pharmaceuticals in a research report on Tuesday, September 20th. They set a “buy” rating and a $66.00 target price for the company. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $51.40.
In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of Aerie Pharmaceuticals stock in a transaction on Friday, July 22nd. The shares were purchased at an average price of $17.50 per share, with a total value of $4,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 8.77% of the stock is owned by company insiders.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc. (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.